


Singapore Therapeutics Development Review (STDR)

Dr Katherine Wang
Deputy Director, STDR
July 2026



Synergies with Partners to Bolster Drug Development Ecosystem



* EDDC and NATi may also work directly with academic partners to co-develop assets in areas of mutual strategic interest.

EPP (Entrepreneur Partner's Programme) partners entrepreneurs with researchers for venture creation.

STDR aims to Boost Local Drug Development & Biotech Pipelines

Objectives



Strengthen **pipeline** of drug
discovery/development projects aimed at
commercialisation



Provide **focused support and guidance** for projects
towards commercial traction via investments by
biopharma and/or venture builders



Develop **biopharma I&E talent** in the local
ecosystem

Activities

Project Evaluation

Project Funding

Pre-Pilot (\$325K including IRC)
Pilot (\$1M including IRC)

Mentorship

Venture Leads Scheme *NEW*

Professional Project Management *NEW*

Project-based Bootcamps

Symposiums/Seminars

Initiatives to Enhance Project Quality & Sharpen Translational Focus

Venture Leads Scheme*

NEW

Objectives

- Lead development of **strategic business plans** to ensure that STDR projects are commercially competitive and attractive to private funders.
- **Entrepreneurial know-how** to complement project teams' scientific expertise to improve odds of commercial success of high-potential STDR projects.

Profile

Biopharma industry experts with strong entrepreneurial drive and proven track record in venture creation and fundraising in the past 5-10 years.

*Venture Leads are to guide high-potential STDR project teams towards follow-on funding, spin out, and raise VC funding.

Professional Project Management

NEW

Objectives

- To engage **professional project managers** to closely monitor the progress of STDR Pilot projects to ensure successful project delivery.
- To provide support to the project teams in incorporating feedback from industry experts and resolving issues.

STDR Strategically Leverages Industry Expertise to Enhance Rigour of Project Evaluation



Dr Andreas Wallnoefer
Former Partner
Jeito Capital



Dr Harald Dinter
Ex SVP
Bayer



Dr Roberto Iacone
Former CEO
Alentis Therapeutics



Prof Damian O'Connell
CEO
EDDC




Prof Charles Cooney
Professor Emeritus
MIT



Ms Margaret Rumpf
Ex VP
GSK



Dr Matthew Jacobson
PD
AIDD



Dr Mohamed ElSayed
ED
NATi

- Rigorous reviews through interactive biotech-like pitch sessions
- Structured guidance to strengthen projects

Bootcamps

Shifting project teams' mindsets towards commercialisation and equipping them with better understanding of commercial and regulatory considerations required for drug development



Venture Exploration	Venture Design	Venture Execution
1. Opportunity Matrix and identification of first application and beachhead market 2. Target Product Profile (TPP) 3. Business Value Proposition 4. Competitive Analysis 5. Art of Pitching and Practice Pitch	1. Deeper dive into TPP 2. Drug Development Roadmap 3. Regulatory Steps 4. Commercialisation Path: Licensing, Partner, and Spin-off 5. Designing Venture for Scale-Up 6. Business Economic Model 7. Financial and Value Creation Plan	1. Team dynamics and role of CXOs 2. How to source for CDMO/CRO 3. Corporate and Patent Law for Entrepreneurs 4. Individualised pitch feedback from bootcamp facilitators and curated list of VCs

Mentors Provide Individualised Guidance on Commercialisation & Connect with Industry Networks

71 project mentors



Amy Schulman
Managing Partner
Polaris Partners



Roberto Iacone
Former CEO
Alentis
Therapeutics



Damian O'Connell
CEO
EDDC



Carl Firth
Partner
Panacea Venture



Charles Cooney
Prof Emeritus
MIT



Hakan Goker
Managing Director
M Ventures



Jack Yin Zheng
Founding Partner
Trinity Bioventure



Harald Dinter
ex SVP
Bayer



Margaret Rumpf
ex VP
GSK



Alice Chen
Partner & Head
APAC
ALSP



Ho Wen Qi
Therapeutics Lead
ClavystBio



David Kolesky
Principal
MPM BioImpact



Adel Nada
Co-founder & CEO
GentiBio



Gaurav Laroia
CSO
Carecentra



Ivan Horak
Founder & CEO
Tikva AlloCell



Flo Chan,
Founder &
Principal Consultant
BioStarter
Consulting



Jeffrey Lu
Founding
Partner
NSG
Ventures



Ken Noonan
ex CEO
Lightstone SG

Training Activities to Improve Ecosystem Knowledge & Develop Entrepreneurial Mindset



Summary

- STDR aims to strengthen local **drug development and biotech pipelines**. We strategically **leverage industry expertise** across all of our initiatives.
- In RIE2030, STDR will place greater emphasis on translating scientific discoveries into viable business opportunities. We will focus on improving project quality and sharpening the translational focus, by strengthening **Project Management** and enhancing support for venture creation through the new **Venture Leads Scheme**.
- STDR will continue to work in close synergy with ecosystem partners and serve as a **national-level funnel** for promising early-stage academic projects to enter downstream translational receptacles (e.g. EDDC, NATi, and pharma/biotech companies).